Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Prion diseases are disorders that share several characteristics that are typical of many neurodegenerative diseases.Recently, several studies have extended the prion concept to pathological aggregation in malignant tumors involving misfolded p53, a tumor-suppressor protein.The aggregation of p53 and its coaggregation with p53 family members, p63 and p73, have been shown.Certain p53 mutants exert a dominant-negative regulatory effect on wild-type (WT) p53.The basis for this dominant-negative effect is that amyloid-like mutant p53 converts WT p53 into an aggregated species, leading to a gain-of-function (GoF) phenotype and the loss of its tumor-suppressor function.Recently, it was shown that p53 aggregates can be internalized by cells and can coaggregate with endogenous p53, corroborating the prion-like properties of p53 aggregates.The prion-like behavior of oncogenic p53 mutants provides an explanation for its dominant-negative and GoF properties, including the high metastatic potential of cancer cells carrying p53 mutations.The inhibition of p53 aggregation appears to represent a promising target for therapeutic intervention in patients with malignant tumors.P rion diseases are disorders that share several characteristics that are typical of many neurodegenerative diseases (Prusiner 1998(Prusiner , 2013(Prusiner , 2014)).Recently, studies have provided evidence that the prion concept may be extended to several neurodegenerative diseases (Silva et al. 2008;Polymenidou and Cleveland 2011;Prusiner 2012;Soto 2012;Irwin et al. 2013).Key pro-teins involved in these diseases, such as Ab, tau, a-synuclein, SOD1, and TDP43, may act as prions, as shown by their transmissibility in animals and in cultured mammalian cells (Polymenidou and Cleveland 2011;Prusiner 2012;Soto 2012;Irwin et al. 2013;Prusiner et al. 2015).These degenerative diseases are based on the prion-like conversion of a correctly folded pro-
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434 · cited 1×
“Amyloid fibril formation has been shown for numerous proteins under the appropriate conditions; however, not all of these proteins are considered prion-like (Bucciantini et al. 2002).”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 1×
“Following DNA damage, phosphorylation of p53 at Ser15, Thr18, and Ser20 dissociates MDM2 from the transactivation domain and increases its affinity for p300/CBP, facilitating p53 transcriptional activity (Kussie et al. 1996; Ferreon et al. 2009; Lee et al. 2010).”
BackgroundPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“Biallelic substitutions are very common in tumor-suppressor genes, but TP53 is most commonly affected by monoallelic alterations, including at six hotspots within the DNA-binding domain (R175, G245, R248, R249, R273, and R282).”
BackgroundMutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“The p53–MDM2 interaction was shown to be critical because the lethality of MDM2-null mice was rescued by the simultaneous deletion of the TP53 gene (Jones et al. 1995; Montes de Oca Luna et al. 1995).”
BackgroundRescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
p63 Is Essential for the Proliferative Potential of Stem Cells in Stratified Epithelia
Senoo, M., Pinto, F., Crum, C. P., & McKeon, F. (2007) · Cell · doi:10.1016/j.cell.2007.02.045 · Cited by 881 · cited 1×
“They show a severe phenotype, lacking limbs and a wide range of epithelial structures, including the skin, prostate, breasts, and urothelia, indicating that p63 is required to maintain the pool of proliferating stem cells during epithelial development (Senoo et al. 2007; Su et al. 2009).”
BackgroundPrion-like transmission of protein aggregates in neurodegenerative diseases
Brundin, P., Melki, R., & Kopito, R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2873 · Cited by 778
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735
MDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648 · cited 1×
“MDMX (HDMX for the human ortholog) is another key regulator of p53 that binds to the transactivation domain of p53 and inhibits its transcriptional activity (Shvarts et al. 1996, 1997; Böttger et al. 1999).”
BackgroundPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Biology and Genetics of Prions Causing Neurodegeneration
Prusiner, S. B. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-110711-155524 · Cited by 455
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 1×
“Alternatively, PRIMA-1, which has shown positive results in stage I/II clinical trials, covalently binds to Cys124 in the p53 DNA-binding domain and restores the functionality of several class I mutants (Lambert et al. 2009; Lehmann et al. 2012; Wassman et al. 2013; Bykov and Wiman 2014).”
BackgroundThe pathological response to DNA damage does not contribute to p53-mediated tumour suppression
Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53
Linares, L. K., Hengstermann, A., Ciechanover, A., Müller, S., & Scheffner, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2030930100 · Cited by 361
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341 · cited 3×
“3) (Xu et al. 2011; Ghosh et al. 2014; Rangel et al. 2014; Soragni et al. 2016).”
BackgroundMDM2 interacts with MDMX through their RING finger domains
Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., & Ohtsubo, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00254-9 · Cited by 324
Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310 · cited 4×
“…partner of MDM2 (Sharp et al. 1999; Tanimura et al. 1999) and contributes to tumor formation, as shown by the retrovirus-mediated MDMX overexpression in primary mouse embryonic fibroblasts, which induced immortalization and neoplastic transformation in combination with HRasV12 (Danovi et al. 2004).”
BackgroundInfluentialAnalysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment
Leroy, B., Girard, L., Hollestelle, A., Minna, J. D., Gazdar, A. F., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22556 · Cited by 224 · cited 2×
“Despite the dominance of nonsynonymous single-nucleotide variants, synonymous single-nucleotide variants, frameshift mutations, silent mutations, splice mutations, CpG dinucleotide transitions, and mutations affecting posttranslational regions of TP53 have also been reported in different tumor types (Leroy et al. 2014…”
BackgroundNeurotoxic protein oligomers — what you see is not always what you get
Bitan, G., Fradinger, E. A., Spring, S. M., & Teplow, D. B. (2005) · Amyloid · doi:10.1080/13506120500106958 · Cited by 221 · cited 1×
“Evidence suggests that, although large amyloid fibrils physically disrupt organelles and tissues, smaller aggregates are more toxic (Buxbaum 2004; Bitan et al. 2005).”
BackgroundHot-spot mutants of p53 core domain evince characteristic local structural changes
Wong, K.-B., DeDecker, B. S., Freund, S. M. V., Proctor, M. R., Bycroft, M., & Fersht, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8438 · Cited by 221
Clinical significance of p53 alterations in surgically treated prostate cancers
Schlomm, T., Iwers, L., Kirstein, P., Jessen, B., Köllermann, J., Minner, S., Passow-Drolet, A., Mirlacher, M., Milde-Langosch, K., Graefen, M., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.104 · Cited by 196 · cited 2×
“Considering the stage of development, a lower frequency of TP53 mutations was reported in primary prostate tumors (between 10% and 20%) than in metastatic tumors (up to 50%) (Schlomm et al. 2008).”
BackgroundComparative study of the p53-mdm2 and p53-MDMX interfaces
Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189 · cited 2×
“MDMX (HDMX for the human ortholog) is another key regulator of p53 that binds to the transactivation domain of p53 and inhibits its transcriptional activity (Shvarts et al. 1996, 1997; Böttger et al. 1999).”
Backgroundp53 ancestry: gazing through an evolutionary lens
Lu, W.-J., Amatruda, J. F., & Abrams, J. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2732 · Cited by 112
MDMX inhibits the p300/CBP-mediated acetylation of p53
Sabbatini, P., & McCormick, F. (2002) · DNA and Cell Biology · doi:10.1089/104454902320219077 · Cited by 62 · cited 2×
“block the p300/CBP-mediated acetylation of p53 (Sabbatini and McCormick 2002), a modification that is critical for the tumor-suppressor functions of p53 (Brooks and Gu 2011).”
Background
Cited by
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
(2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.08.002 · Cited by 78
Self-citation
Metadata
- Authors
- Costa, D. C. F., de Oliveira, G. A. P., Cino, E. A., Soares, I. N., Rangel, L. P., & Silva, J. L.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-08-22
- Volume
- 8
- Issue
- 10
- Pages
- a023614
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2515276046
- Cited by
- 89
- References
- 33
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.